Initial Statement of Beneficial Ownership (Form 3)

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * LYNCH TIMOTHY P 2. Date of Event Requiring Statement (Month/Day/Year) 08/19/2026 3. Issuer Name and Ticker or Trading Symbol AEON Biopharma, Inc. [AEON] (Last) (First) (Middle) 70 SW CENTURY DR., STE. 100 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below) 5. If Amendment, Date Original Filed (Month/Day/Year) (Street) BEND, OR 97702 6. Individual or Joint/Group Filing (Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Class A Common Stock 5,350,000 D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Pre-Funded Warrants	(1)	(1)	Class A Common Stock	1,000,000(2)	$0.0001	D
Warrants	07/15/2026	(3)	Class A Common Stock(4)	3,000,000(2)	$0.3221	D
Warrants	07/15/2026	(5)	Class A Common Stock(6)	3,000,000(2)	$0.3704	D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
LYNCH TIMOTHY P 70 SW CENTURY DR. STE. 100 BEND, OR 97702		X

Signatures

/s/ Timothy P. Lynch		08/21/2026
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The pre-funded warrants are exercisable at any time and have no expiration date.
(2)	The reporting person (together with his affiliates) may not exercise any portion of these warrant to the extent that, after giving effect to such exercise, the reporting person would beneficially own more than 4.99% of the outstanding shares of Class A Common Stock immediately after exercise. The beneficial ownership limitation may be increased or decreased at the reporting person's election to a percentage not in excess of 19.99%, upon at least 61 days' prior written notice to us, subject to the terms of the warrants.
(3)	These warrants will expire on the earlier of (i) the second anniversary of the date of issuance and (ii) the 45th day following the Issuer's public announcement that it has received Type 2B meeting minutes from the FDA regarding certain matters.
(4)	At the option of the reporting person, each of these warrants may be exercised for either one share of Class A Common Stock or one pre-funded warrant to acquire Class A Common Stock.
(5)	These warrants will expire on the earlier of (i) the fifth anniversary of the date of issuance and (ii) 45 days following the Issuer's public announcement that the Issuer has initiated a Phase 3 clinical equivalence trial of ABP-450 as a biosimilar to BOTOX.
(6)	At the option of the reporting person, each of these warrants may be exercised for either one share of Class A Common Stock or one pre-funded warrant to acquire Class A Common Stock.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.